Pharmacokinetics of amantadine in children with impaired consciousness due to acquired brain injury: preliminary findings using a sparse-sampling technique.
OBJECTIVE
To evaluate the pharmacokinetics of amantadine in children with impaired consciousness from acquired brain injury.


METHODS
Randomized, double-blind, placebo-controlled, crossover study with sparse sampling for pharmacokinetics.


METHODS
Tertiary care pediatric hospital.


METHODS
Children, ages 6-18 years, with impaired consciousness 5-10 weeks after acquired brain injury.


METHODS
Subjects received amantadine for 3 weeks. Subjects were randomized to placebo or amantadine 4 mg/kg/day for 7 days followed by 6 mg/kg/day for 14 days. Crossover was after a 7-day washout period.


METHODS
The Coma/Near-Coma Scale and Coma Recovery Scale-Revised were done 3 times per week to evaluate arousal and consciousness. Plasma concentrations of amantadine were determined for pharmacokinetic parameter estimation and evaluation of the exposure-response relationship. Adverse events were monitored.


RESULTS
Nine subjects met the final inclusion and exclusion criteria, 7 of whom agreed to participate. Five subjects completed both arms of the study. Amantadine total body clearance was 0.17 L/h/kg with a half-life of 13.9 hours. Higher exposure of amantadine (average concentration of amantadine during 6 mg/kg/day > 1.5 mg/L) may be associated with better recovery of consciousness.


CONCLUSIONS
Amantadine was well-tolerated in children with acquired brain injury and demonstrates pharmacokinetics similar to those reported for healthy young adults. Based on the preliminary data, higher dosing may be considered in the setting of brain injury.
Vargus-Adams
Jilda N
JN
Department of Physical Medicine & Rehabilitation and Pediatrics, Center for Epidemiology and Biostatistics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229-3039, USA. jilda.vargus-adams@cchmc.org
McMahon
Mary A
MA
Michaud
Linda J
LJ
Bean
Judy
J
Vinks
Alexander A
AA
D000293:Adolescent; D000547:Amantadine / Q000493:pharmacokinetics*; D001930:Brain Injuries / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D002648:Child; D003243:Consciousness / Q000187:drug effects / Q000502:physiology*; D003244:Consciousness Disorders / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D018592:Cross-Over Studies; D015259:Dopamine Agents / Q000493:pharmacokinetics*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D020127:Recovery of Function / Q000187:drug effects*; D016896:Treatment Outcome
D015259:Dopamine Agents; D000547:Amantadine